SecBot SecBot
PRESS-RELEASE ·Filed May 4, 2026

TLX

Telix Pharmaceuticals Limited
BULLISH
Impact 5/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Monitor for additional studies or regulatory updates that could expand TLX250-Px's label to non-clear cell RCC, which would increase the addressable market.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.04
T+0 close · May 4, 2026 · via day close
Latest settled
−8.88%
T+60 · $10.06
Vs SPY
−11.62%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $11.04entry
  2. T+1 · 7mo ago +0.63%α −0.75% · $11.11
  3. T+5 · 6mo ago −5.89%α −7.87% · $10.39
  4. T+20 · 6mo ago −17.03%α −21.98% · $9.16
  5. T+60 · 4mo ago −8.88%α −11.62% · $10.06

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Telix announced publication of exploratory Phase 3 ZIRCON data in European Urology showing TLX250-Px PET/CT is highly predictive of renal malignancy across all subtypes, not just ccRCC, with a 98% positive predictive value. While this expands the potential utility of the imaging agent, the analysis is exploratory and not part of the pending BLA for ccRCC.

Key Facts

  • TLX250-Px PET/CT showed 98% positive predictive value for renal malignancy across all subtypes in exploratory analysis of ZIRCON trial data.
  • Results published in European Urology, a leading peer-reviewed journal.
  • The data are exploratory and not part of the BLA submission for ccRCC.

Financial Impact

No immediate financial impact; potential label expansion supports long-term value.

Risk Factors

  • TLX250-Px is not yet approved for any indication; BLA for ccRCC remains the near-term catalyst.
  • Exploratory data may not replicate in prospective studies or regulatory submissions.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3287198

Track record

27 reports on TLX

Performance horizon

9 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.

Filters
  1. Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
  2. Oct 20, 202627d ago 6-K Neutral 4/10 No price data
  3. Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
  4. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
  5. Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  6. Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  7. Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
  8. Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (10h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026